No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
Your Way to Confidence
Enter the world of SeQuent® DCB treatment with cutting-edge balloon technology and a proven leader at your side – for more drug options, more clinical data, high-quality support and the confidence you’re aiming for.
This information is meant for medical professionals only. Please confirm that you are a medical professional before accessing this information.
Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional."Non-flow limiting dissections (type A–C) tend to heal over time after DCB treatment
[with SeQuent® Please NEO]."
CardiovascularNews (Nov 2025, Issue 79) explores why coronary dissections may not, after all, have to be a cause for alarm. Read the full article to learn about recent studies and expert insights – and why device choice matters for long-term outcomes.
Read the full articleInterventional cardiologists often fear the occurrence of dissections after PCI, but when using a drug-coated balloon there can be occasions when dissections have a healing effect.
This was one of many talking points when Patrick W. Serruys (National University of Ireland, Galway) sat down with Cardiovascular News to discuss why dissections should not be feared when performing DCB-PCI with the SeQuent® Please NEO.
Guided by expertise
Leading experts from around the globe share their experiences with drug coated balloons. Dive deep into their DCB practices and gain unique insights, all guided by real-world experience and expert knowledge.
Clinical evidence
B. Braun has been at the forefront of DCB technology from the start – opening up and confirming best-practice options for drug coated balloons with both paclitaxel and sirolimus. B. Braun’s longterm commitment to the DCB field has established an impressive record of clinical evidence – and offers a dynamic way forward, regardless of your preferred treatment drug.
It’s the special crystalline coating of SeQuent® DCBs that makes the most of a DCB’s short period of inflation. Confirmed through large clinical data sets, the sharp-edged spike structures of the crystals ensure the drug’s persistence in the vessel wall.
Paclitaxel coated balloon
Indications
SeQuent® Please NEO is continuously expanding its unique evidence-based position.Clinically proven, it offers new procedural options for the cardiologists in their daily cath lab routine as it has been investigated in a variety of indications and challenging patient populations such as:
Indications/clinical scenarios | SeQuent® Please NEO | References |
| In-stent restenosis | ✓ | 2-28 |
| De novo lesions | ✓ | 5, 7, 11, 15, 29-49 |
| Small vessel disease | ✓ | 29, 32-34, 36-37, 40, 45, 50, 51-53 |
| Large vessel disease | ✓ | 29, 35, 39, 41-44, 46 |
| Bifurcations | ✓ | 5, 11, 16, 47-48, 54-60 |
| Acute coronary syndromes | ✓ | 11, 52, 61-63 |
| STEMI | ✓ | 11, 52, 64-65 |
| NSTEMI | ✓ | 11, 52, 63, 66 |
| High bleeding risk | ✓ | 39, 46, 67-68 |
| Diabetes mellitus | ✓ | 9, 33, 52, 69-73 |
| Chronic kidney disease | ✓ | 50 |
| Multivessel disease | ✓ | 11, 69, 74 |
| Chronic total occlusion | ✓ | 11, 75-80 |
| Elderly patients (>75 years) | ✓ | 81 |
SeQuent® Please NEO
> 0
published studies
> 0
documented patients
> 0
countries
2020 | Primary Investigator: Jeger R | Study Aim: SQP vs. DES, Vessel: RD ≤ 3 mm | (Primary) Endpoint: MACE @ 36-month follow-up | Patients: 758
Summary BASKET-SMALL 22017 | Primary Investigator: Funatsu A | Study Aim: DCB vs. POBA, Vessel: RD ≤ 2.75 mm, ≥ 2 mm | (Primary) Endpoint: TVF @ 6-month follow-up | Patients: 135
Summary PEPCAD Japan SVD2017 | Primary Investigator: Gobić D | Study Aim: DCB vs. DES, Patients: STEMI (< 12 h) | (Primary) Endpoint: MACE, LLL @ 6-month follow-up | Patients: 75
Summary AMI Feasibility Study2016 | Primary Investigator: Nishiyama N | Study Aim: DCB vs. DES | (Primary) Endpoint: TLR @ 8-month follow-up | Patients: 60
Summary Clinical Value "Stent-less" PCI2019 | Primary Investigator: Rosenberg M | Study Aim: DCB – ISR & De Novo | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 1,025
Summary DCB-only All-Comers Registry2016 | Primary Investigator: Shin E | Study Aim: DCB – De Novo, Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | (Primary) Endpoint: LLL, FFR @ 9-month follow-up, MI, TLR @ 12-month follow-up | Patients: 67
Summary FFR-Guided DCB-Angioplasty2014 | Primary Investigator: Zeymer U | Study Aim: DCB – De Novo, Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 447
Summary SVD Registry2023 | Primary Investigator: Shin ES | Study Aim: Investigate the impact of DCB-based treatment on PCI for multivessel CAD | (Primary) Endpoint: MACE @ 24-months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding) | Patients: 508
Summary DCB-based PCI in Multi-Vessel-DiseaseSirolimus coated balloon
B. Braun´s sirolimus coated balloon is the first SCB backed up with published randomized clinical trials for ISR and de-novo lesions.82, 83, 84 SeQuent® SCB offers new implant-free options for treating coronary ISR and de-novo lesions, providing excellent results in targeted drug delivery and sirolimus persistence. The combination of sirolimus and BHT (Butylated Hydroxy Toluol) creates the desired crystalline sirolimus modification to reach best results regarding sirolimus vessel wall content compared to other excipients.85
Sirolimus + BHT (Butylated Hydroxy Toluol): Persistence in the vessel wall
Read moreTwo RCTs for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.
Read summaryRCT for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.
Read summary
